First Patients Dosed with Cabaletta Bios Rese-cel Manufactured on Cellares' Automated Cell Shuttle Platform
Cellares, the first Integrated Development and Manufacturing Organization (IDMO), today announced that Cabaletta Bio Inc.s (Cabaletta Bio or Cabaletta) (Nasdaq: CABA) investigational CAR T cell therapy rese-cel (resecabtagene autoleucel) has been infused into the first two patients using drug...